HC Wainwright Issues Positive Forecast for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at HC Wainwright increased their Q2 2025 earnings estimates for shares of Neurocrine Biosciences in a note issued to investors on Tuesday, May 6th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $0.63 for the quarter, up from their previous estimate of $0.58. HC Wainwright currently has a “Buy” rating and a $168.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences’ Q3 2025 earnings at $1.17 EPS, FY2026 earnings at $4.19 EPS and FY2029 earnings at $13.44 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.62). The business had revenue of $572.60 million during the quarter, compared to analysts’ expectations of $587.06 million. Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Neurocrine Biosciences’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.20 EPS.

A number of other research analysts have also recently weighed in on the company. Wedbush restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Tuesday. Needham & Company LLC upped their price objective on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the company a “buy” rating in a research note on Tuesday. Bank of America cut their price target on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a report on Friday, February 7th. Evercore ISI decreased their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Finally, UBS Group upped their target price on Neurocrine Biosciences from $137.00 to $152.00 and gave the company a “buy” rating in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $162.00.

Neurocrine Biosciences Price Performance

NBIX opened at $115.71 on Thursday. Neurocrine Biosciences has a 1-year low of $84.23 and a 1-year high of $157.98. The stock has a market cap of $11.45 billion, a P/E ratio of 35.17, a P/E/G ratio of 0.77 and a beta of 0.26. The stock’s 50 day simple moving average is $106.23 and its 200 day simple moving average is $121.80.

Neurocrine Biosciences declared that its Board of Directors has initiated a stock repurchase plan on Friday, February 21st that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Insider Activity

In related news, Director William H. Rastetter sold 30,000 shares of Neurocrine Biosciences stock in a transaction on Monday, May 5th. The shares were sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the sale, the director now owns 37,491 shares of the company’s stock, valued at $4,131,508.20. The trade was a 44.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Matt Abernethy sold 2,558 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $116.86, for a total transaction of $298,927.88. Following the completion of the transaction, the chief financial officer now directly owns 34,775 shares of the company’s stock, valued at approximately $4,063,806.50. The trade was a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 43,907 shares of company stock worth $4,935,982. 4.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds have recently made changes to their positions in the stock. OneDigital Investment Advisors LLC grew its stake in shares of Neurocrine Biosciences by 2.1% in the fourth quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company’s stock worth $575,000 after purchasing an additional 87 shares in the last quarter. HighPoint Advisor Group LLC increased its stake in Neurocrine Biosciences by 4.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company’s stock valued at $334,000 after buying an additional 96 shares during the period. Huntington National Bank lifted its stake in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock worth $31,000 after acquiring an additional 97 shares during the period. Louisiana State Employees Retirement System boosted its holdings in shares of Neurocrine Biosciences by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,100 shares of the company’s stock valued at $3,836,000 after acquiring an additional 100 shares in the last quarter. Finally, Utah Retirement Systems increased its stake in shares of Neurocrine Biosciences by 0.6% during the fourth quarter. Utah Retirement Systems now owns 16,583 shares of the company’s stock valued at $2,264,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.